Background The need for preventive therapies that interrupt the progression of Alzheimer's
disease (AD) before the onset of symptoms or when symptoms are emerging is urgent and …

As the focus of Alzheimer's disease (AD) therapeutic development shifts to the early stages
of the disease, the clinical endpoints used in drug trials, and how these might translate into …

Older adults with lower education are at greater risk for dementia. It is unclear which brain
changes lead to these outcomes. Longitudinal imaging-based measures of brain structure …

Objective To test the hypothesis that plasma total tau (t-tau) and neurofilament light chain
(NfL) concentrations may have a differential role in the study of frontotemporal lobar …

More than 20 genetic loci have been associated with risk for Alzheimer's disease (AD), but
reported genome-wide significant loci do not account for all the estimated heritability and …

Objective: Growing evidence suggests that vascular risk factors (VRF) contribute to cognitive
decline. The aim of this study was to investigate the impact of VRF on the conversion from …

Objective Reactive astrogliosis is a hallmark of Alzheimer's disease (AD) and frontotemporal
dementia (FTD) but differences between the diseases and time course are unclear. Here, we …

Introduction Despite the clinical implementation, there remain significant gaps in our
knowledge regarding the impact of race/ethnicity or common medical comorbidity on plasma …

Objective: To describe the phenotype of patients with C9FTD/ALS (C9ORF72)
hexanucleotide repeat expansion. Methods: A total of 648 patients with frontotemporal …

Objective To examine the validity and reliability of the MMSE-2 for assessing patients with
mild cognitive impairment (MCI) and Alzheimer's disease (AD) in a Korean population …